Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Phase 1/2 Completed 38 enrolled AbbVie Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.

Timeline

Start: 2014-09-22
Primary completion: 2021-03-12
Completion: 2021-03-12

Publications

Background Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitadine	Unknown	75 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	500 mg/m2	—
Subject	Venetoclax	Small molecule	—	—

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Summary

Timeline

Publications

Drugs

Indications